title: Treatment with biosynthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion.
abstract: OBJECTIVE
  Impairment of linear growth is a common clinical feature in patients with beta-thalassaemia major. Although growth hormone secretion appears to be normal in many short thalassaemic patients, it proves to be deficient in some of them. In these cases, administration of biosynthetic growth hormone seems justified. The aim of this study was to evaluate the effect of such treatment in a group of patients with beta-thalassaemia major presenting with growth failure and impairment of growth hormone secretion.
  
  
  METHODS
  Recombinant human growth hormone, 0.6 U/kg body weight per week, given subcutaneously in three divided doses, was administered for 12 months.
  
  
  METHODS
  Eight prepubertal patients with beta-thalassaemia major, presenting with severe growth retardation and impaired growth hormone secretion in response to provocative stimuli (insulin-induced hypoglycaemia, L-dopa and growth hormone-releasing hormone), were investigated.
  
  
  METHODS
  Height and pubertal stage of the patients, as well as plasma levels of insulin-like growth factor I, were determined before, during and after biosynthetic growth hormone treatment.
  
  
  RESULTS
  During the first 6 months of therapy, a significant increase of growth velocity was observed, from a mean pretreatment value of 2.1 +/- 0.45 cm/year to a value of 4.8 +/- 0.66 cm/year (P less than 0.002). Mean growth rate at 12 months (4.1 +/- 0.50 cm/year), though slightly decreased in comparison to that recorded at 6 months, was still significantly higher than basal (P less than 0.001). A significant increase in plasma levels of insulin-like growth factor I was recorded during treatment (2.82 +/- 0.47 vs 0.96 +/- 0.22 U/ml, P less than 0.005). No side-effects, adverse reactions or alterations in routine laboratory examinations ensued during or after therapy.
  
  
  CONCLUSIONS
  It appears from these data that biosynthetic growth hormone administration is worth serious consideration in patients with beta-thalassaemia major presenting growth retardation and impaired growth hormone secretion.
authors.affiliation: Italian Auxologic Center, Milan.
authors.forename: M
authors.initials: M
authors.lastname: Scacchi
authors.forename: L
authors.initials: L
authors.lastname: Danesi
authors.forename: M
authors.initials: M
authors.lastname: De Martin
authors.forename: A
authors.initials: A
authors.lastname: Dubini
authors.forename: L
authors.initials: L
authors.lastname: Forni
authors.forename: A
authors.initials: A
authors.lastname: Masala
authors.forename: D
authors.initials: D
authors.lastname: Gallisai
authors.forename: C
authors.initials: C
authors.lastname: Burrai
authors.forename: S
authors.initials: S
authors.lastname: Terzoli
authors.forename: C
authors.initials: C
authors.lastname: Boffa
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D013006:Growth Hormone / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013789:Thalassemia / Q000097:blood / Q000150:complications*
chemical_list: D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone